High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BMC Pulmonary Medicine

Table 1 Patient characteristics

Case no.	Age	Sex	PS	Tumor type	Stage	Smoking history	Treatment line	Treatment cycle	Diagnosis to treatments	Initiation of nivolumab to onset of pneumonitis	Radiographic pattern	Distribution	Major lesion	CTCAE grade pneumonitis	Treatment for pneumonitis	Outcome of penumonitis	Survival from initiations of nivolumab
1	71	Male	1	MM	IV	No	2nd	1	61 months	17 days	NSIP	Bilateral	Lt lower lobe	1	None	Remission	158 days
2	46	Male	1	NSCLC	IV	No	4th	1	23 months	12 days	COP	Bilateral	Rt upper lobe	3	Corticosteroids	Remission	109 days
3	58	Male	1	NSCLC	IV	54	7th	1	43 months	13 days	COP	Bilateral	Rt upper lobe	3	Corticosteroids	Remission	172 days
4	58	Male	1	HNC	Iva	52.5	5th	2	36 months	18 days	COP	Right	Right	3	Corticosteroids	Remission	156 days

PS performance status, MM malignant melanoma, NSCLC non-small cell lung cancer, HNC head and neck cancer, CTCAE common terminology criteria for adverse events V4.0, NSIP nonspecific interstitial pneumonia, COP cryotpgenic organizing pneumonia, Lt left, Rt right

ISSN: 1471-2466